Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT05489731
What this trial is testing

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. 72
Large-scale testing (Phase 3)Study completedNCT02438722
What this trial is testing

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network 174
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Testing effectiveness (Phase 2)Looking for participantsNCT04335292
What this trial is testing

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Who this might be right for
Non-Small Cell Lung Cancer
Mark Vincent 200
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Testing effectiveness (Phase 2)UnknownNCT02274337
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Early research (Phase 1)Ended earlyNCT02448251
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
ACEA Therapeutics, Inc. 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07298148
What this trial is testing

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Who this might be right for
NSCLC Stage IVEGFR Positive Non-small Cell Lung CancerEGFR-TKI Sensitizing Mutation
Peking University Cancer Hospital & Institute 28
Large-scale testing (Phase 3)Temporarily pausedNCT05378763
What this trial is testing

Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 268
Not applicableUnknownNCT04768491
What this trial is testing

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Activating MutationNSCLC Stage IVNSCLC Stage IIIB+1 more
Peking Union Medical College 82
Large-scale testing (Phase 3)Active Not RecruitingNCT06670196
What this trial is testing

SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 420
Testing effectiveness (Phase 2)Looking for participantsNCT06706713
What this trial is testing

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc 200
Testing effectiveness (Phase 2)Study completedNCT03046992
What this trial is testing

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Gene Mutation
Yuhan Corporation 224
Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Early research (Phase 1)Study completedNCT02442414
What this trial is testing

KBP-5209 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd. 35
Not applicableUnknownNCT04397432
What this trial is testing

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Tian Xie 878
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Not applicableStudy completedNCT01788163
What this trial is testing

Asia Pacific and Russia Diagnostic Study for EGFR Testing

Who this might be right for
EGFR Mutation Status in aNSCLC Patients
AstraZeneca 3,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07710612
What this trial is testing

ABSK043 Combined With Osimertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Abbisko Therapeutics Co, Ltd 72
Next Page